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Introduction
Idiopathic pulmonary fibrosis (IPF) occurs in genetically 
susceptible individuals who are exposed to different 
environmental risks factors. It is associated with repetitive 
injury to the alveolar epithelium and subsequent activation 
of development pathways and aberrant immune and 
inflammatory signaling that results in the remodeling of the 
affected lungs. Patient with IPF are commonly older adults 
exhibiting heterogeneity in clinical course of the disease 
with a median survival of 2 to 3 years (1,2).
IPF has common risk factors with cancer and significant 
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similarities in the pathobiology process, both diseases 
having poor outcomes (3,4).
Immune checkpoint PD-1 is one of the essential 
inhibitory molecules for controlling inflammatory response 
to injury in the normal lung tissues. Programmed death 
ligand-1/programmed cell death 1 (PD-L1/PD-1) axis 
represents a relevant negative feedback loop for maintaining 
immune homeostasis, but it is also of crucial importance for 
restricting tumour immunity (5,6). Transforming growth 
factor-β (TGF-β), a key growth factor in the pathogenesis 
of IPF, but also a significant pleiotropic cytokine for lung 
cancer, has the ability to modulate response to immune 
checkpoint inhibitors (5).
Tumors have the ability to escape from immunosurveillance 
and keep an immunosuppressive microenvironment which 
is stimulative for their unrestricted growth through multiple 
pathways. Among those is immunomodulation of T-cell 
response through downregulation of co-stimulatory 
molecules or enhancement of co-inhibitory molecules 
including immune checkpoints on T cells, other immune 
cells and tumor cells (5,6). PD-L1 expressed on tumor 
and tumor-associated cells bounds to immune checkpoint 
PD-1 on cytotoxic T cells blocking their activation and 
proliferation.
Checkpoint inhibitor agents targeting PD-1/PD-L1 
liberate antitumor T cells from the blockade enabling their 
further activation, proliferation and killing tumor cells. This 
cancer immunotherapy has revolutionized treatment and 
outcomes in several cancers including lung cancer.
Membrane-bound PD-1 and PD-L1 (mPD-1 and 
mPD-L1) also have soluble forms, the finding contributing 
to the complexity and multiplicity of the PD-1/PD-L1 
(B7-H1/CD274) immunomodulation pathway (7-9).
Abundant mousse and human data released recently 
clearly point that checkpoint regulatory molecules are 
essential in some autoimmune diseases, not only in 
cancer (10,11).
In a recently published study, RNA sequencing pointed 
to CD274 as significantly downregulated gene in human 
IPF lung tissue obtained by surgical biopsy (12).
We have undertaken this pilot study to evaluate which 
of the several cell types involved in IPF development 
and present in human IPF lung tissue exhibit immune 
checkpoint PD-L1 expression being positive for PD-L1 
test, and to test if soluble forms of PD-L1, soluble PD-L1 
(sPD-L1) can be detected in significant concentrations 
in blood of IPF patients which might be even considered 
potential diagnostic or prognostic biomarkers. 
Methods
PD-L1 expression in IPF tissue samples
The same human IPF lung tissue samples (formalin-
fixed, paraffin-embedded, FFPE) of our 12 patients in 
which RNA sequencing pointed to CD274 as significantly 
downregulated gene, have been tested for PD-L1 
expression. IPF was diagnosed in those patients by IPF 
Multidisciplinary Team, based on clinical-radiological 
criteria according to guidelines and histologic confirmation 
of UIP pattern. Lung tissue specimens were obtained by 
surgical biopsy, minor thoracotomy with biopsy, with the 
diameter of those biopsy samples ranging from 3 to 4.8 cm.
P D - L 1  I H C  2 2 C 3  p h a r m D x ,  a  q u a l i t a t i v e 
immunohistochemical assay using monoclonal mouse anti-
PD-L1, Clone 22C3 has been used in the detection of 
PD-L1 protein in FFPE human IPF lung tissue samples. 
EnVision FLEX visualization system on Autostainer Link 
48 was used. 
PD-L1 protein expression was determined by using 
Tumor Proportion Score (TPS), which is the percentage 
of viable cells [in this study alveolar macrophages (AMs)] 
showing partial or complete membrane staining. The 
specimen was considered PD-L1 positive if TPS ≥50% 
of the viable AMs exhibited membrane staining at any 
intensity.
Plasma samples preparation and storing
Plasma samples for examination of sPD-L1 forms, PD-L1 
(B7-H1/CD274) blood concentration determination, 
originated from our alive 23 patients with IPF who did not 
undergo surgical biopsy. IPF in those patients was made by 
IPF Multidisciplinary Team, based on clinical-radiological 
criteria according to guidelines. These plasma samples 
were separated by using BD Vacutainer lithium-heparin 
tubes (Becton Dickinson, Heidelberg, Germany) for blood 
collection and centrifuged for 15 minutes at 1,000 ×g, 
within 30 minutes of collection. Aliquoted plasma samples 
were stored at −80 ℃ until analysis (maximally 6 months 
after the blood drawing).
PD-L1 (B7-H1/CD274) blood concentration 
determination 
For the PD-L1 (B7-H1/CD274) determination in human 
plasma was used DuoSet ELISA system (R&D systems 
Europe, Ltd. Abingdon, UK), as a sandwich enzyme-linked 
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immunosorbent assay (ELISA) specific for the human 
B7-H1. Results are reported in ng/L; in our hands the 
lower detection limit was 2.0 ng/L, the upper limit of the 
test linearity was 1,250 ng/L. According to manufacturer’s 
data reference values for healthy people in heparin-plasma 
samples are 33–110 ng/L.
The study was approved by School of Medicine Belgrade 
University Ethics and Review Board of 06.06.2017 (No. 
61206-2299/2-17).
Results
PD-L1 expression in IPF tissue samples
One of our goals was to explore mPD-L1 (clone 22C3) 
positivity in FFPE lung fibrosis tissue samples. Our study 
involved FFPE human lung tissue samples of twelve patients 
with IPF. Histological parameters included fibroblastic foci, as 
well as hypertrophic myofibroblast fibres, AMs or other present 
immune cells investigated for positivity to PD-L1 (Table 1). 
We have found that PD-L1 expression on fibroblast and 
myofibroblast membrane was negative in all twelve cases of 
IPF. PD-L1 expression in IPF AMs was negative in three 
cases, but there was positivity to overexpression of PD-L1 
in nine IPF cases. Only very few cells in the interstitium 
have shown discrete PD-L1 expression, but none of a 
membrane type (Table 1 and Figure 1).
Soluble PD-L1 concentration in IPF patients and in 
healthy subjects
In order to compare lung disease biomarkers in IPF patients 
with healthy people, we have performed Kruskal-Wallis 
nonparametric ANOVA test followed by Mann-Whitney 
U test, as a post-hoc test, where appropriate. Twenty-three 
patients included had newly diagnosed IPF who did not 
undergo surgical lung biopsy (Table 2).
We have found elevated concentrations of sPD-L1 
in the serum of IPF patients, significantly higher 
compared with healthy control group, 314.3 ng/L 
(117.7–483.1 ng/L) versus 91.0 ng/L (52.4–119.7 ng/L), 
respectively (P<0.01). And not only that: sPD-L1 levels 
in IPF patients were significantly higher compared with 
sPD-L1 levels in newly diagnosed non-small cell lung 
cancer (NSCLC) patients (study results in press). Results 
are presented in the Table 3. Moreover, our results showed 
that sPD-L1 blood concentration is significantly higher 
in patients who had stage II IPF compared to IPF stage I 
group (estimated according to GAP score).
Discussion
IPF has common risk factors with cancer and significant 
similarities in the pathobiology process, regarding variety of 
genetic, epigenetic, cellular and molecular aspects and both 




Age at the time 
of biopsy (years)
Diagnosis





1 F 65 IPF 3 3 Large >50 + PD-L1(−)
2 F 49 IPF 3 3 Moderate >1, <50 [20] + PD-L1(−)
3 F 38 IPF 2 2 Small <1 − PD-L1(−)
4 M 56 IPF 1 1 Small >1, <50 [40] + PD-L1(+ up to 5%)
5 F 39 IPF 3 3 Large >50 + PD-L1(+ up to 5%)
6 M 68 IPF 1 1 Large >50 + PD-L1(−)
7 M 59 IPF 2 1 Small <1 − PD-L1(−)
8 F 68 IPF 2 3 Small <1 − PD-L1(−)
9 F 58 IPF 1 1 Moderate >1, <5 + PD-L1(−)
10 F 51 IPF 3* 3 Moderate <50 [40] + PD-L1(−)
11 M 37 IPF 3* 2 Moderate >1 [5] + PD-L1(−)
12 M 61 IPF 3* 3 Moderate >1 [10] + PD-L1(−)
*, Honey comb lung. IPF, idiopathic pulmonary fibrosis.
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diseases have poor outcome (3,4).
Immune checkpoint is one of the essential inhibitory 
molecules for controlling inflammatory response to injury 
in the normal lung tissues, and considered relevant in the 
pathogenesis of both IPF and lung cancer. Risk factors such 
as smoking and occupational and environmental exposures 
result in stimulus producing repetitive epithelial lung 
injury leading to abnormal wound healing predisposing to 
genetic mutations, and ultimately occurrence of IPF and 
lung cancer. Patients with IPF have an increased risk for 
lung cancer (4). On the other hand, pulmonary toxicity, 
fibrosing pneumonitis, as an immune-related adverse 
event of immunotherapy with anti-PD-1/PD-L1 agents is 
more common in patients with NSCLC than in patients 
with other tumor types, and clinical trials with anti-PD-1 
and anti-PD-L1 agents excluded patients with underlying 
Figure 1 Programmed cell death-ligand-1 (PD-L1) expression in alveolar macrophages in different histological stages of usual 
interstitial pneumonia pattern (idiopathic pulmonary fibrosis). (A) Cystic remodeling of lung parenchyma (“honeycomb changes”) 
(H&E, ×20); (B) PD-L1 expression: >1% positivity in alveolar macrophages; intensity of expression +1 (×20); (C) fibroblastic foci and 
moderate interstitial inflammation (H&E, ×20); (D) PD-L1 expression: >50% positivity in alveolar macrophages; intensity of expression 
+2 (×20); (E) fibroblastic foci and moderate interstitial inflammation (H&E, ×20); (F) PD-L1 expression: >50% positivity in alveolar 
macrophages; intensity of expression +2 (×20); (G) cystic remodeling of lung parenchyma (H&E, ×20); (H) PD-L1 expression: >1% 
positivity in alveolar macrophages; intensity of expression +1 (×20); (I) fibroblastic foci, smooth muscle proliferation and moderate interstitial 
inflammation (H&E, ×20); (J) PD-L1 expression: >50% positivity in alveolar macrophages; intensity of expression +2 (×20).
A B C D
E F G H
I J
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Table 2 Baseline characteristics and clinical course of 23 newly diagnosed IPF patients
Patients, 
number 
Gender Age (years) Diagnosis
Stage of fibrosis (GAP 
score)
Type to the outcome Outcome itself
1 F 65 IPF I Slow progression Died
2 F 76 IPF II Slow progression Died, CVI
3 M 69 IPF III Slow progression Died, CVI
4 M 50 IPF I Slow progression Alive, dementia
5 F 68 IPF II Slow progression Died
6 M 87 IPF II Fast progression Died
7 F 66 IPF I Slow progression Alive, stable disease
8 M 73 IPF/Ca II Slow progression Died, Ac. exacerbation
9 F 68 IPF II Slow progression Alive
10 M 63 IPF II Fast progression Alive
11 F 56 IPF I Slow progression Alive
12 F 69 IPF II Slow progression Alive, stable disease
13 F 69 IPF I Slow progression Alive, stable disease
14 F 58 IPF I Slow progression Alive, stable disease
15 F 62 IPF II Slow progression Alive, stable disease
16 M 60 IPF I Slow progression Alive, stable disease
17 F 60 IPF I Slow progression Alive, stable disease
18 F 80 IPF I Slow progression Alive, stable disease
19 F 54 IPF I Fast progression Alive
20 F 42 IPF II Fast progression Died, Ac. exacerbation
21 F 83 IPF II Slow progression Alive
22 F 85 IPF II Slow progression Alive, stable disease
23 M 69 IPF III Slow progression Alive, stable disease
IPF, idiopathic pulmonary fibrosis; Ca, cancer; Ac., acute; CVI, cerebrovascular insult. 
interstitial lung disease (ILD) (13).
Key finding in this pilot study is that mPD-L1 (over) 
expression was evidenced on AMs in 9 out of 12 IPF cases. 
Under physiological conditions, AMs are critical for lung 
homeostasis and respiratory functions, not only surfactant 
clearance within the alveolar space (14), but also in directing 
pulmonary immune responses to pathogens and regulating 
tissue damage by suppressing immune responses (15). 
AMs colonize the lung within the first few days of life and 
have impressive self-renewal properties, the predominant 
mechanism for macrophage renewal being by expansion in 
situ (16,17).
Although there are obvious differences among the 
namely M2 macrophages, regulatory macrophages, 
tumor associated macrophages (TAM) and myeloid 
derived suppressor cells (MDSC) subsets, they all exhibit 
immune suppressive activity (14,18) and, consequently, 
when stimulated, macrophages adopt context-dependent 
phenotypes that either promote or inhibit host antimicrobial 
defense, anti-tumour immunity and inflammatory 
responses. There is evolving evidence that macrophages 
represent a spectrum of activated phenotypes rather than 
discrete stable subpopulations (18). Numerous studies have 
documented their plasticity, with macrophages switching 
from one functional phenotype to another in response to 
the variety of microenvironmental signals (18). 
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Since IPF is shown to be linked to the ageing process, 
AMs as long-lived cells have gained a lot of attention for 
potential profound implications for the clinical course and 
outcomes of IPF. The differentiation between recruited 
and resident macrophages seem to be important for the 
pathogenesis of fibrosis since the kind and function of 
produced cytokines can vary significantly between resident 
and recruited macrophages (16). AMs, in contrast to most 
other tissue macrophages, are shown to be dependent 
on transforming growth factor-b receptor (TGF-βR) 
signaling. TGF-β is crucial for the differentiation of fetal 
monocytes into preAMs during embryonic development, 
their maturation after birth, as well as for the homeostasis 
of adult AMs (16,18). The source of TGF-β is AMs 
themselves, indicative of an autocrine loop that promotes 
AM self-maintenance while TGF-β are activated by AMs in 
an autocrine manner as well (15).
Macrophages are key regulators of fibrosis and they 
produce numerous pro-fibrotic soluble mediators, 
chemokines,  and matrix  metal loproteases.  In the 
normal repair response to injury, macrophages acquire 
a phenotype which promotes fibroproliferation, so thus 
“pro-fibrotic” macrophages (also called M2) produce 
various mediators, pro-fibrotic cytokines and chemokines, 
including TGF-β1, that directly activate fibroblasts and 
regulate the proliferation and survival of myofibroblasts, 
thus controlling extracellular matrix (ECM) deposition 
as well (16,19). Pro-fibrotic macrophages also directly 
secrete matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs), regulators of 
inflammatory cell recruitment and ECM turnover (16). 
Although macrophages are necessary for the initiation 
and maintenance of fibrosis, some studies suggested that 
they were also required in the suppression, resolution 
and reversal of fibrosis and thus, with their ability to both 
initiate and inhibit fibrosis, macrophages are highly relevant 
for all stages of the fibrotic process. Based on numerous 
findings, macrophages seem to get distinct roles exhibiting 
a predominant phenotype dependent on the specific stage 
of fibrotic process (16,19).
Our study results show that PD-L1 is overexpressed on 
AMs in IPF biopsy tissue samples, although not in the same 
extent in all of them. We have found that PD-L1 expression 
in IPF AMs was negative in three IPF cases, but there was 
positivity to overexpression of PD-L1 in nine IPF cases. 
Only very few cells in the interstitium have shown discrete 
PD-L1 expression, but not of a membrane type. PD-L1 
expression on fibroblast and myofibroblast membrane was 
negative in all twelve cases of IPF.
It is well known that monocytes and macrophages 
function also as antigen-presenting cells  sending 
costimulatory and coinhibitory signals to T cells (20), 
thus with ability to promote Th2 responses (21) which 
induce and activate TGF-β1 in macrophages through an 
IL-13- and MMP9-dependent mechanism (20).  By 
expressing immuno-inhibitory ligands, such as PD-L1, 
macrophages can suppress T cell immunity. Binding of 
PD-L1 to PD-1 expressed by T cells create an inhibitory 
signal that blocks the activity of T cells and this PD-L1/
PD-1 axis is an important negative feedback loop that 
ensures immune homeostasis, but also the way tumours 
effectively escape detection and suppress immune responses. 
PD-L1 high tumor-associated macrophages block the 
activity of tumor infiltrating cytotoxic T cells, antitumor 
T cells. Recognition of the role of PD-1/PD-L1 pathway 
in downregulating the activity of effector T cells within 
tumors and peripheral tissues has led to the development of 
cancer immunotherapy—checkpoint inhibitor therapy, that 
target PD-L1 expression on cancer and tumor-associated 
cells liberating antitumor T cells to proliferate and kill 
cancer cells (6).
Suppress ion  o f  the  cy totox ic  T ce l l  re sponse 
may be directed by macrophages within the tumor 
microenvironment via expression of B7 family ligands 
(PD-L1, B7-H4), or indirect through release of IL-10 or 
recruitment of IL-10-expressing regulatory T cells (TReg). 
In the latter, IL-10 suppresses the ability of dendritic cells 
to produce IL-12 and promote a Th1/cytotoxic T cell anti-
tumor immune action (6). Response rates to treatment with 
checkpoint inhibitors in the clinical trials relate in part to 
PD-L1 expression in tumor stroma concordant with the 
functions of macrophages, and/or other stromal cells, in 
blocking anti-tumor T cell responses (6,22).
It should be noted that PD-1 is expressed not only in 
T cells, but also in TAMs, which become inactivated upon 
binding to PD-L1 expressed on tumor cells. TAMs with 
Table 3 sPD-L1 concentration in sub-groups according to IPF stage
Parameter
IPF stage (GAP score)
P value
I II
sPD-L1 (ng/L) 162.4 (85.4–263.7) 303.6 (249.2–572.5) 0.025
Data are presented as median values (50th percentile) and (25th-
75th percentile); P value from the Mann-Whitney U test. IPF, 
idiopathic pulmonary fibrosis. sPD-L1, soluble programmed 
death ligand-1.
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M2 phenotype (M2 TAMs) express PD-L1 as well as the 
ligand for the death receptor, FAS, that inactivates T cells 
and triggers their death. Treatment with the checkpoint 
inhibitor enables activation of cytotoxic T cells, but also 
increases phagocytic ability of TAMs against tumor cells. 
PD-1-positive TAMs show reduced phagocytic ability 
compared with PD-1 negative TAMs, further diminished if 
co-existent tumor cells express PD-L1 (23,24).
The novel finding on M2 TAMs expressing PD-1 
and PD-L1 and its implications (23), may contribute 
to the knowledge about the roles of the PD-1/PD-L1 
pathway not only in the tumor but also in other immune 
microenvironment involving different immune cells. We 
could think of similar scenario with this novel finding in 
immuno-oncology translated from lung cancer to IPF, 
speculating how immune cells, especially monocytes and 
macrophages, foster fibrosis through molecular processes 
other than known as “proinflammatory” pathways.
Similar to TAMs, IPF macrophages may display 
two phenotypes, inflammatory M1 and a predominant 
alternatively activated M2 phenotype. This M2 phenotype 
exhibits marked expression of arginase, chitinase-like 
and resistin-like molecules (24,25) and ability to promote 
secretion of fibroblast growth factors (including PDGF 
and FGF2), profibrotic cytokines including TGF-β 
and interleukin (IL)-13 (26) and plasminogen activator 
inhibitor (PAI)-1 and MMPs (24). Moreover, recently 
shown in murine models of lung fibrosis, fibrocytes have 
no role in the collagen deposition (27) thus suggesting that 
macrophages (or their monocyte precursors) are of crucial 
importance in IPF (28).
Lung-resident macrophages may exhibit significant 
phenotypic plasticity that may be dependent on different 
stimuli or a microenvironment and thus M1/M2 phenotypes 
are considered more as a dynamic spectrum of activation 
potentially explaining some of the heterogeneity of IPF 
(16,29,30).
When tissues are damaged, inflammatory mediators 
are released, macrophages often display an inflammatory 
M1-like phenotype, among other activities secrete MMPs 
such as MMP2 and MMP9 that help to degrade the ECM 
and enable the influx of inflammatory cells to the site of 
tissue injury (16,28,29,31).
If the tissue-damaging factor persists, activated M1 
cells can further exacerbate the inflammatory response by 
different mechanisms, leading to profound tissue damage. 
When the inflammatory stimulus is discontinued, M1 
cell activation decreases, subsequent conversion of the 
immune response into a wound healing response occurs, 
with the accumulation of M2 macrophages that foster 
healing process and fibrosis through the secretion of 
MMPs (MMP12), TIMP1, growth factors and cytokines 
such as TGF-β1. In the final phase, macrophages take on a 
regulatory/suppressive phenotype, which is featured by the 
expression of PD-L2 and IL-10 among others, which have 
all been shown to restore homeostasis while suppressing 
fibrotic process, partly by blocking T cell proliferation and 
collagen synthesis by activated myofibroblasts (16,29).
Regarding our study f indings  that  mPD-L1 is 
overexpressed only in AMs in IPF biopsy tissue samples, 
it might be speculated that PD-L1 positive AMs have 
regulatory/suppressive phenotype with reduced degree of 
phagocytosis (as is the case with PD-L1-positive TAMs) 
and might reflect a specific IPF phenotype failing to limit 
the development of fibrosis and restore homeostasis.
Heterogeneity  in the incit ing st imuli ,  genet ic 
predisposition and signaling mechanisms that promote 
profibrotic cell phenotypes may, like cancer, contribute to 
different clinical courses observed in patients with IPF that 
reflect different IPF Phenotypes. Thus, IPF with AMs PD-
L1 overexpression might be a specific IPF phenotype, or 
at least a particular IPF development phase. If so, then the 
approach to IPF, and fibrotic disease in general, may benefit 
from a similar precise medical approach.
Those novel finding on PD-1/PD-L1 axis and its 
implications (23), led to investigation of the potential 
roles of the PD-1/PD-L1 pathway both, in the tumor and 
other immune microenvironments. Co-inhibitory and co-
stimulatory immune checkpoint receptors are necessary 
for full T-cell activation, and impaired tolerance causes 
the occurrence of majority of autoimmune diseases. There 
has already been evidence that PD-1 has a key “first-line” 
inhibitory impact on the majority of autoimmune diseases. 
However, genetic pattern influences the relative impact of 
their ligands B7.1, B7.2 and PD-L1, PD-L2, respectively. 
The influencing factors can also be the timing of ligand 
expression and interaction, as well as cell types expressing 
different one or other, and the specific cellular mechanisms 
underlying each disease (10,11).
Emerging data suggest that immune checkpoint axes 
are dysregulated in chronic obstructive pulmonary disease 
(COPD) as well. Within diseased lungs, T-cells express 
the key receptor PD-1 and exhibit loss of their cytotoxic 
function, but there is also evidence of downregulation of the 
associated ligand PD-L1 on AMs. It is speculated that the 
resulting impact may be excessive T-cell inflammation due 
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to acute infection, which may contribute to the pattern of 
COPD exacerbation and lung damage (32).
Pulmonary toxicity with anti-PD-1 agents is more 
common in patients with NSCLC than in patients with 
other tumor types, which is possibly due to impaired 
immune tolerance resulting from smoking-induced 
changes in the normal lungs. It is postulated that removal 
of checkpoint controls leads to excessive T-cell activation, 
tissue inflammation and damage, but all possibly important 
underlying factors are not still known (13). The reason 
lung cancer patients with underlying mild IPF or other 
fibrotic ILD were excluded from clinical trials with 
immunotherapy for lung cancer, checkpoint inhibitors, 
was the fear of the IPF/ILD deterioration, having in 
mind sometimes life-threatening pulmonary toxicity as 
an immune-related adverse event to immunotherapy with 
PD-1/PD-L1 checkpoint inhibitors. There are however 
increasing number of case reports on lung cancer patients 
with concomitant mild IPF or other fibrotic ILD who 
were treated with anti-PD-1/PD-L1 agents with good 
disease control and a no IPF/fibrotic ILD deterioration, 
so elucidation of some kind of individual background or 
susceptibility to immune-related toxicity pneumonitis is 
needed in the future (33).
Recent studies have discovered that mPD-1 and 
mPD-L1 also have soluble forms, and there are findings 
pointing to the profound complexity of the PD-1/PD-L1 
axis  (7) .  The soluble  forms of  PD-1 and PD-L1 
(sPD-1 and sPD-L1) evaluated in the blood of cancer 
patients may originate from proteolytic cleavage of the 
membrane-bound form, or by translation of alternative 
spliced mRNA. Both immune and tumor cells can be 
sources of sPD-L1, but as it is a characteristic of myeloid-
derived cells, it seems that there is another regulatory 
mechanism controlling the release of sPD-L1, different 
from that of mPD-L1. Since no correlation was noted 
between tumor PD-L1 expression and sPD-L1 levels, 
this implies that the tumor microenvironment, including 
nonmalignant cells, might also produce sPD-L1 (7,26). 
The precise roles  of  these molecules  have not 
been elucidated yet, but a number of ongoing studies 
are trying to estimate their significance in human 
malignancies and evaluate their potential diagnostic, or 
prognostic and predictive biomarkers. Recent findings 
suggest that the blood levels of sPD-1/PD-L1 might 
predict treatment response and outcomes in cancer 
patients (3,7,8).
The data show that sPD-L1 is normally detected in 
human serum with the levels increasing with age (26). It 
has been shown that the production of sPD-L1 can be 
suppressed by MMP inhibitors. These findings might 
be the explanation for the high serum concentrations of 
PD-L1 soluble forms in IPF patients (11,26). We have 
found significantly higher concentrations of sPD-L1 in 
the serum of IPF patients compared with healthy control 
group, 314.3 versus 91.0 ng/L respectively (P<0.01). It 
has also been noticed that sPD-L1 levels in IPF patients 
were significantly higher compared with sPD-L1 levels in 
newly diagnosed NSCLC patients (reported study results in 
press). The question of precise functions of sPD-L1 in IPF, 
as well as in cancer and other autoimmune diseases, must be 
raised. The sPD-1/PD-L1 seem to be unrecognized factor 
that participate in immune response as well, but at present, 
whether sPD-L1 can bind to PD-1, similarly to mPD-L1, 
and act as an inhibitory signal is not clear. The findings of 
in vitro experiments where PD-1 or PD-L1 fusion proteins 
are added cause remarkably increased T-cell proliferation 
with expression of mPD-1 or mPD-L1. It implies that 
the abilities of mPD-1 and mPD-L1 are upregulated by 
their soluble forms. There are some controversial results 
regarding prognostic impact of high serum concentrations 
PD-L1 in different tumors (7,9,34,35).
Our study findings of elevated concentrations of 
sPD-L1 in the serum of IPF patients, are significantly 
higher compared with healthy control group, and sPD-L1 
levels in IPF patients are significantly higher compared 
with also significantly elevated sPD-L1 levels in newly 
diagnosed NSCLC patients (reported study results). Above 
mentioned results, require further investigations in a larger 
patients’ population. Accumulated data at present indicate 
that sPD-1 and sPD-L1, which can be easily estimated 
in clinical practice, may have very important roles in 
immunopathogenesis and potential to reflect treatment 
responses, not only in tumors, but in IPF and other 
autoimmune disorders as well. It may be speculated that 
sPD-1/PD-L1 might be new biomarkers with significant 
impact on potential treatment strategies including 
immunotherapy in variety of diseases. 
This is a pilot study that has several limitations. Perhaps, 
the most prominent is a small number of human IPF lung 
tissue samples that has been included in this research, thus 
not allowing reliable evaluation of this novel findings and 
clear conclusions. Larger number of IPF tissue samples is 
needed for the further research in order to elucidate the 
significance of PD-L1 expression in AMs in a complex 
molecular pattern of IPF, and the impact of PD-L1, 
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PD-L2/PD-1 axis in IPF. Another limitation is that we 
have not investigated bronchoalveolar lavage (BAL) for 
PD-L1 expression in AMs and other cells, which is going 
to be the next step. A small number of IPF patients were 
included in the study which has shown the significantly 
elevated concentrations of sPD-L1 in the serum of IPF 
patients. Thus, there is a need for more confirmatory 
studies, validation and new studies comparing this potential 
biomarker in different interstitial diseases in order to define 
its prognostic and/or predictive role.
Conclusions
IPF with AMs PD-L1 overexpression might be a specific 
IPF phenotype, or just an IPF development phase. Many 
questions raised from similarities in the pathobiology of IPF 
and lung cancer need answers. Based on these similarities 
and common expression of a number of growth factors, 
some lung cancer drugs have already been translated into 
treatment option for IPF (Nintedanib). This is a pilot 
study of membrane immune checkpoint PD-L1 expression 
in human IPF lung tissue samples and of soluble sPD-L1 
plasma concentrations in IPF patients. For IPF with 
PD-L1 overexpression of AMs, further studies are necessary 
in order to elucidate this phenomenon and to potentially 
consider investigating some new treatment modalities 
or drug combinations as well. As for sPD-1 and sPD-L1 
accumulated data at present indicate that they can be easily 
detected in clinical practice, and more importantly may have 
significant roles in immune responses and prediction not 
only in tumors, but in IPF and other autoimmune disorders 
as well. It may be speculated that sPD-1/PD-L1 should be 
evaluated as new prognostic or/and predictive biomarkers to 
aid potential treatment strategies including immunotherapy 
in the variety of diseases. 
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